Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance
European Journal of Nuclear Medicine and Molecular Imaging · 2026-04 · 53 (5) · 3042-3055
DOI: 10.1007/s00259-025-07645-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 09.12.2025. Verfasst von Levent Kabasakal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye. lkabasakal@tsnm.org. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Patient Selection, Oligopeptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To develop and validate the Istanbul [68Ga]Ga-PSMA PET/CT Criteria (IPPC), a standardized imaging framework designed to identify clinically significant prostate cancer (csPCa) and improve selection of candidates for active surveillance (AS). METHODS: [68Ga]Ga-PSMA PET/CT scans and histopathology from 163 men with biopsy-proven International Society of Urological Pathology (ISUP) Grade Group (GG) 1-2 prostate cancer who underwent radical prostatectomy were retrospectively reviewed by a multidisciplinary panel of nuclear medicine physicians, radiologists, and urologists. Imaging characteristics-including uptake pattern, morphology, localization, and SUVmax-were iteratively analyzed to define three categories: IPPC-1 (indolent), IPPC-2 (indeterminate), and IPPC-3 (csPCa-suspected). Delayed pelvic acquisitions were used as the primary dataset to enhance lesion definition and interpretability. Reproducibility was evaluated in 56 GG1 patients using Cohen's and Fleiss' κ statistics. Correlations between PSA, SUVmax, and IPPC categories were assessed, and ROC curve analysis was performed to determine the optimal SUVmax threshold for csPCa detection. RESULTS: Pathological upgrading occurred in 40% of all cases (74% GG1, 20% GG2). Among 56 GG1 patients, upgrading was 76%. SUVmax and PSA were significantly higher in IPPC-3 than in IPPC-2 (SUVmax 16.3 vs. 6.5, p < 0.001; PSA 7.8 vs. 5.3 ng/mL, p < 0.05). ROC analysis yielded an AUC = 0.76 with an optimal SUVmax cut-off of 8.21 (sensitivity 55%, specificity 90%). All lesions with SUVmax ≥ 12.0 corresponded to csPCa. Interobserver agreement was substantial (κ ≈ 0.70-0.74) and intraobserver concordance strong (κ ≈ 0.80-0.90), confirming high reproducibility. CONCLUSION: IPPC provides a reproducible, biologically grounded method that integrates SUVmax, morphology, and anatomical localization to non-invasively refine AS eligibility. By identifying patients at genuine risk for csPCa while minimizing unnecessary biopsies, IPPC may improve confidence and adherence in AS management. Prospective multicentre validation within the ongoing I-SELECT trial (NCT07168616) will determine its broader clinical applicability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye. lkabasakal@tsnm.org.
- Medical Faculty, Department of Nuclear Medicine, Yeditepe University , Istanbul, Türkiye. lkabasakal@tsnm.org.
- Medical Faculty, Department of Nuclear Medicine, Yeditepe University , Istanbul, Türkiye.
- Department of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Türkiye.
- Department of Nuclear Medicine, Yedikule Chest Disease and Surgery Training and Research Hospital, Istanbul, Türkiye.
- Department of Radiology, University of Health Sciences, Haseki Training and Research Hospital, Istanbul, Türkiye.
ORCID-Profile: Levent Kabasakal, Kaan Akçay, Alan Nalan Selçuk, Gamze Beydağı, Elife Akgün, Reşit Akyel, Türkay Toklu, Rüştü Türkay, Saadettin Eskiçorapçı, Burcu Esen Akkaş, Umut Elboğa, Halil Kömek, Elif Çıngı Özdemir, Onur Erdem Şahin, Ali Rıza Kural
Zitieren
APA
Kabasakal, L., Akçay, K., Selçuk, A. N., Beydağı, G., Akgün, E., Akyel, R., Toklu, T., Türkay, R., Eskiçorapçı, S., Akkaş, B. E., Elboğa, U., Kömek, H., Özdemir, E. Ç., Şahin, O. E., & Kural, A. R. (2026). Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance. European Journal of Nuclear Medicine and Molecular Imaging, 53(5), 3042-3055. https://doi.org/10.1007/s00259-025-07645-w
Vancouver
Kabasakal L, Akçay K, Selçuk AN, Beydağı G, Akgün E, Akyel R, et al. Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(5):3042-3055. doi:10.1007/s00259-025-07645-w
BibTeX
@article{Kabasakal2026,
author = {Kabasakal, Levent and Akçay, Kaan and Selçuk, Alan Nalan and Beydağı, Gamze and Akgün, Elife and Akyel, Reşit and Toklu, Türkay and Türkay, Rüştü and Eskiçorapçı, Saadettin and Akkaş, Burcu Esen and Elboğa, Umut and Kömek, Halil and Özdemir, Elif Çıngı and Şahin, Onur Erdem and Kural, Ali Rıza},
title = {Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {5},
pages = {3042--3055},
doi = {10.1007/s00259-025-07645-w}
}
EUVIMED